Marker Therapeutics Inc. (NASDAQ: MRKR) stock jumped 63.64% on Friday to $0.54 against a previous-day closing price of $0.33. With 73.45 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.38 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.6600 whereas the lowest price it dropped to was $0.4900. The 52-week range on MRKR shows that it touched its highest point at $2.17 and its lowest point at $0.25 during that stretch. It currently has a 1-year price target of $2.88. Beta for the stock currently stands at 1.27.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MRKR was up-trending over the past week, with a rise of 69.28%, but this was up by 49.96% over a month. Three-month performance surged to 61.24% while six-month performance fell -3.43%. The stock lost -74.53% in the past year, while it has lost -43.17% so far this year. A look at the trailing 12-month EPS for MRKR yields -0.52 with Next year EPS estimates of -0.41. For the next quarter, that number is -0.13. This implies an EPS growth rate of 10.30% for this year and 6.80% for next year.
Float and Shares Shorts:
At present, 83.11 million MRKR shares are outstanding with a float of 66.66 million shares on hand for trading. On Jul 14, 2022, short shares totaled 1.12 million, which was 1.34% higher than short shares on Jun 14, 2022. In addition to Mr. Peter L. Hoang MBA as the firm’s Pres, CEO & Director, Mr. Anthony H. Kim serves as its Chief Financial Officer.
Through their ownership of 28.61% of MRKR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.50% of MRKR, in contrast to 32.44% held by mutual funds. Shares owned by individuals account for 12.52%. As the largest shareholder in MRKR with 4.25% of the stake, Eastern Capital Ltd. holds 3,550,001 shares worth 3,550,001. A second-largest stockholder of MRKR, Aisling Capital Management LP, holds 3,142,857 shares, controlling over 3.76% of the firm’s shares. Long Focus Capital Management LLC is the third largest shareholder in MRKR, holding 2,435,863 shares or 2.91% stake. With a 2.85% stake in MRKR, the USAA Science & Technology Fund is the largest stakeholder. A total of 2,378,629 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 1.56% of MRKR stock, is the second-largest Mutual Fund holder. It holds 1,300,503 shares valued at 0.43 million. Vanguard Extended Market Index Fu holds 1.04% of the stake in MRKR, owning 869,815 shares worth 0.29 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2022, MRKR reported revenue of $0.00 and operating income of -$9.79M. Over the past year, revenue came in at $1.24M while operating income stood at -$40.49M. It generated -$9.91M net income for the quarter, which came to -$43.01M over the last twelve months. The EBITDA in the recently reported quarter was -$8.84M and diluted EPS was -$0.12. EBITDA for the full year was -$37.13M.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MRKR since 4 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MRKR analysts setting a high price target of $5.00 and a low target of $1.00, the average target price over the next 12 months is $2.88. Based on these targets, MRKR could surge 825.93% to reach the target high and rise by 85.19% to reach the target low. Reaching the average price target will result in a growth of 433.33% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. MRKR will report FY 2022 earnings on 03/16/2023. Analysts have provided yearly estimates in a range of -$0.36 being high and -$0.48 being low. For MRKR, this leads to a yearly average estimate of -$0.42. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Marker Therapeutics Inc. reported -$0.12 EPS against a consensus estimate of -$0.12. The surprise factor in the prior quarter was $0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.04 and the low estimate is -$0.14. The average estimate for the next quarter is thus -$0.10.
Summary of Insider Activity:
Insiders traded MRKR stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 3 while that of sell transactions has risen to 3 over the past year. The total number of shares bought during that period was 490,429 while 117,917 shares were sold.